tiprankstipranks
Trending News
More News >
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
US Market
Advertisement

Arvinas Holding Company (ARVN) AI Stock Analysis

Compare
1,017 Followers

Top Page

ARVN

Arvinas Holding Company

(NASDAQ:ARVN)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 4o)
Rating:49Neutral
Price Target:
$7.50
▼(-0.40% Downside)
Arvinas' overall score is primarily impacted by its financial challenges, including persistent losses and declining revenue. While there are positive developments in clinical trials and strategic initiatives, these are offset by revenue decline and restructuring costs. Technical indicators suggest a neutral trend, but valuation remains unattractive due to ongoing losses.
Positive Factors
Clinical Trial Progress
Progress in clinical trials, including KRAS G12D degrader ARV-806, indicates strong R&D capabilities and potential future revenue streams.
Partnership with Novartis
The partnership with Novartis enhances Arvinas' market position and provides significant financial opportunities through milestones and royalties.
Cash Runway Extension
Extending the cash runway provides financial stability, allowing Arvinas to focus on long-term strategic initiatives and R&D efforts.
Negative Factors
Revenue Decline
Declining revenue, especially from key collaborations, poses a risk to financial health and may impact future growth and investment capacity.
Restructuring Costs
High restructuring costs reflect operational challenges and could strain financial resources, affecting long-term profitability.
Pfizer Collaboration Issues
Issues with the Pfizer collaboration may hinder drug development progress and reduce potential revenue from co-commercialization.

Arvinas Holding Company (ARVN) vs. SPDR S&P 500 ETF (SPY)

Arvinas Holding Company Business Overview & Revenue Model

Company DescriptionArvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
How the Company Makes MoneyArvinas generates revenue through several key streams, primarily from partnerships and collaborations with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales of the drugs developed using Arvinas's technology. Additionally, the company may receive grant funding for specific research initiatives. The success of Arvinas's revenue model heavily relies on the advancement of its therapeutic candidates through clinical trials and into commercialization, as well as the strength and scale of its partnerships in the biopharmaceutical sector.

Arvinas Holding Company Earnings Call Summary

Earnings Call Date:Aug 06, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 11, 2025
Earnings Call Sentiment Neutral
The call highlighted significant progress and achievements in clinical trials and partnerships, notably with Novartis and the NDA submission for Vepdeg. However, challenges such as revenue decline, restructuring costs, and issues with the Pfizer collaboration were noted. The sentiment is balanced between positive developments and significant challenges.
Q2-2025 Updates
Positive Updates
Strong Pipeline Progress
Significant strides in early-stage programs with enrollment in 3 Phase I trials, including a KRAS G12D degrader ARV-806, and compelling data from ARV-102 and ARV-393.
Partnership with Novartis
Luxdegalutamide, licensed to Novartis, is advancing rapidly with two new Phase II trials, with potential milestones and royalties up to $1 billion.
Financial Restructuring and Cash Runway
Company-wide restructuring extended cash runway into the second half of 2028, reducing workforce by one-third, and reprioritizing research pipeline.
NDA Submission for Vepdeg
Submitted the first-ever NDA for a PROTAC, with data from VERITAC-2 trial showing potential best-in-class monotherapy profile.
Negative Updates
Revenue Decline
Revenue decreased by $54.1 million compared to the previous year, primarily due to decreased revenue from Novartis License Agreement and removal of two Phase III trials from the Pfizer collaboration.
Restructuring Costs
Restructuring costs amounted to $7.4 million in cash expenses due to employee-related expenses and workforce reduction.
Pfizer Collaboration Issues
The decision to remove combination pivotal trials from development plans with Pfizer led to reconsidering the 50-50 co-commercialization agreement.
Company Guidance
During the second quarter of 2025 earnings call, Arvinas provided an extensive update on its strategic initiatives and financial position. The company announced significant progress in clinical trials, including three Phase I trials across its neuro and oncology portfolios, particularly highlighting their KRAS G12D degrader ARV-806 and LRRK2 degrader ARV-102. A noteworthy accomplishment was the submission of a new drug application for vepdeg, the first PROTAC degrader to achieve this milestone. Financially, Arvinas reported $22.4 million in revenue for the quarter, a decline from the previous year, primarily due to decreased revenue from Novartis and Pfizer collaborations. The company also implemented a restructuring plan, extending its cash runway into the second half of 2028, with $861.2 million in cash, cash equivalents, and marketable securities as of June 30, 2025. Arvinas is actively negotiating with Pfizer to optimize the development and commercialization strategy for vepdeg, considering either adjusting the economics of their collaboration or seeking a new partner should Pfizer decide to return the rights.

Arvinas Holding Company Financial Statement Overview

Summary
Arvinas Holding Company faces significant financial challenges, with persistent losses and declining revenue growth. While the company maintains a strong gross profit margin and low leverage, its negative cash flow from operations and inability to generate profits from equity are concerning. The company needs to focus on improving operational efficiency and revenue growth to enhance its financial health.
Income Statement
45
Neutral
Arvinas Holding Company shows a high gross profit margin, indicating efficient cost management. However, the company struggles with negative net profit and EBIT margins, reflecting ongoing losses. Revenue growth is negative in the TTM, suggesting declining sales, which is concerning for future profitability.
Balance Sheet
50
Neutral
The company maintains a low debt-to-equity ratio, indicating minimal leverage and financial risk. However, the negative return on equity highlights the company's inability to generate profits from shareholders' equity, which is a significant concern.
Cash Flow
40
Negative
Arvinas has a negative operating cash flow, indicating challenges in generating cash from operations. The free cash flow growth is positive, but the high free cash flow to net income ratio suggests reliance on non-operational activities for cash generation, which may not be sustainable.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue372.80M263.40M78.50M131.40M53.60M25.90M
Gross Profit371.40M263.40M78.50M131.40M53.60M21.80M
EBITDA-115.70M-243.60M-394.80M-255.00M-182.40M-117.60M
Net Income-72.60M-198.90M-367.30M-282.50M-191.00M-119.30M
Balance Sheet
Total Assets909.30M1.09B1.30B1.27B1.58B717.37M
Cash, Cash Equivalents and Short-Term Investments861.20M1.04B1.26B1.21B1.50B688.53M
Total Debt9.90M9.70M3.20M5.50M5.00M4.10M
Total Liabilities300.00M529.70M644.60M703.90M799.90M75.11M
Stockholders Equity609.30M561.70M660.00M564.90M781.70M642.26M
Cash Flow
Free Cash Flow-399.00M-261.10M-350.70M-280.30M554.70M-96.20M
Operating Cash Flow-396.40M-259.30M-347.80M-273.50M559.40M-89.76M
Investing Cash Flow347.70M34.70M203.50M242.80M-1.31B164.25M
Financing Cash Flow3.30M7.90M374.70M4.70M278.60M504.67M

Arvinas Holding Company Technical Analysis

Technical Analysis Sentiment
Negative
Last Price7.53
Price Trends
50DMA
7.47
Positive
100DMA
7.36
Positive
200DMA
11.17
Negative
Market Momentum
MACD
0.04
Positive
RSI
47.55
Neutral
STOCH
22.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARVN, the sentiment is Negative. The current price of 7.53 is below the 20-day moving average (MA) of 7.75, above the 50-day MA of 7.47, and below the 200-day MA of 11.17, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 47.55 is Neutral, neither overbought nor oversold. The STOCH value of 22.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARVN.

Arvinas Holding Company Risk Analysis

Arvinas Holding Company disclosed 74 risk factors in its most recent earnings report. Arvinas Holding Company reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Arvinas Holding Company Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
816.67M47.5127.62%35.89%0.00%
60
Neutral
409.48M9.5112.90%1263.40%0.00%
49
Neutral
$552.83M-35.41%
48
Neutral
832.62M-10.18-15.91%83.36%22.27%
39
Underperform
488.40M-3.010.00%-80.09%60.14%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ARVN
Arvinas Holding Company
7.53
-16.13
-68.17%
ANAB
AnaptysBio
20.95
-11.39
-35.22%
MGTX
Meiragtx Holdings
8.15
4.13
102.74%
CMPX
Compass Therapeutics
3.38
1.65
95.38%
OLMA
Olema Pharmaceuticals
8.79
-3.61
-29.11%
BCAX
Bicara Therapeutics Inc.
10.50
-15.80
-60.08%

Arvinas Holding Company Corporate Events

Product-Related AnnouncementsRegulatory Filings and Compliance
Arvinas and Pfizer’s FDA Nod for Cancer Drug
Positive
Aug 8, 2025

On August 8, 2025, Arvinas, in collaboration with Pfizer, announced that the FDA accepted their New Drug Application for vepdegestrant, a PROTAC ER degrader, for treating ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. This acceptance, based on the Phase 3 VERITAC-2 trial, marks a significant step forward as vepdegestrant demonstrated improved progression-free survival compared to fulvestrant, potentially offering a new treatment option for patients with limited alternatives after first-line therapy.

The most recent analyst rating on (ARVN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 17, 2025